Description: Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Home Page: www.sobi.com
Tomtebodavägen 23A
Solna,
112 76
Sweden
Phone:
46 86 97 20 00
Officers
| Name | Title |
|---|---|
| Dr. Guido Oelkers | CEO & Pres |
| Dr. Anders Ullman M.D., Ph.D. | Head of R&D & Medical Affairs and Chief Medical Officer |
| Mr. Henrik Stenqvist | Chief Financial Officer |
| Ms. Christine Wesstrom | Head of Technical Operations |
| Mr. Thomas Kudsk Larsen | Head of Communication & Investor Relations |
| Mr. Torbjörn Hallberg | Gen. Counsel and Head of Legal Affairs & HR |
| Mr. Daniel Rankin | Head of Strategy & Corp. Devel. |
| Pablo de Mora | Head of Global Marketing & Access |
| Mr. Philip Wood | Head of Haematology |
| Ms. Konstantina Karampela | Sr. Director of European Commercial Operations (Specialty Care and Partner Products) |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 16.2075 |
|---|---|
| Trailing PE: | 22.5498 |
| Price-to-Book MRQ: | 2.5094 |
| Price-to-Sales TTM: | 3.6681 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1555 |